Currently Enrolling Studies
Below is a list of our currently enrolling studies. These are always changing so be sure to come back and check for new studies. Scroll below the "featured study" to find the other enrolling studies.
Please do not hesitate to contact us with any questions at (509) 623-9768.
Full List of Studies:
Have you recently been diagnosed with Wet Macular Degeneration? The primary objectives of the study are to determine the safety of high-dose aflibercept and to determine if HD provides greater intraocular pharmacodynamic effect and/or longer duration of action compared to intravitreal aflibercept injection.
This study will evaluate the safety, tolerability, and efficacy of intravitreal injections of RO7171009 administered every 4 weeks (Q4W) or every 8 weeks (Q8W) for approximately 76 weeks in participants with geographic atrophy (GA) secondary to age-related macular degeneration (AMD) compared with sham control.
Do you have age-related macular degeneration (AMD)? Consider participating in the SCOPE study to help advanceAMD research! The SCOPE study is a Natural History research study that will gather information on your disease and how it develops over time. You will not receive any treatment as a study participant. The first step is providing a saliva sample in a tube to see if you qualify. Click the photo below to take the first step!
Do you have age-related macular degeneration (AMD)? Consider participating in the Catalina study to help advance AMD research! This is a multi-center evaluation in a randomized, double-masked, sham-controlled study in participants with Geographic Atrophy Secondary to Age-related Macular Degeneration.
This Study Will Evaluate the Efficacy, Safety, and Pharmacokinetics of the Port Delivery System With Ranibizumab (PDS) in Participants With Diabetic Macular Edema (DME) Compared With Intravitreal Ranibizumab.
This is a Randomized Study in Participants with Diabetic Retinopathy (DR) Without Center-Involved Diabetic Macular Edema (CI-DME) to Evaluate the Efficacy, Safety of the Port Delivery System with Ranibizumab (PDS) Relative to the Comparator Arm.
This is an observational, multicenter study to determine the prevalence of Cerebrotendinous Xanthomatosis (CTX) in patient populations diagnosed with early-onset idiopathic bilateral cataracts. Patients who are potentially eligible for study participation will be identified through a chart review of patients who were seen at each study site prior to that site's initiation, or by entering care at the site while the site is participating in the trial.